Fig. 5 | Nature Communications

Fig. 5

From: Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response

Fig. 5

Anti-tumor activity of TRuC-T and CAR-T cells in lymphoma and leukemia tumor NSG xenograft models. a Raji-LUC tumor growth curves for individual mice upon treatment with CD19 ε-TRuC-T (light blue), 28ζ CAR-T (red), or BBζ CAR-T (purple) cells along with non-transduced (NT) control T cells (black). 5 × 105 Raji tumor cells were subcutaneously injected in the flanks of NSG mice (n = 7 per group). Mice were treated with a single injection of the indicated T cell dose 3 days after injection of tumor cells, survival and tumor size was analyzed over 38 days. Survival curves were analyzed using the Log-rank (Mantel-Cox) test (***P < 0.0001). Data represent results from two independent experiments. b Growth curves of systemic Raji-LUC tumors upon treatment with CD19 ε-TRuC-T, CD19 28ζ CAR-T, CD19 BBζ CAR-T cells, or non-transduced (NT) control T cells. NSG mice (n = 5 per group) were injected with 5 × 105 Raji-LUC cells into the tail vein of mice 5 days prior to treatment with 1 × 107 non-transduced (NT) or engineered T cells. Tumor growth was monitored by bioluminescence imaging. Results from one experiment are shown. c Efficacy of CD19 ε-TRuC-T, CD19 28ζ CAR-T, CD19 BBζ CAR-T cells against disseminated Nalm6-LUC tumor cells. NT, non-transduced control T cells. NSG mice (n = 5 per group) were intravenously injected with 5 × 105 Nalm6-LUC cells. Five days later, mice were treated with a single dose of 5 × 106 non-transduced (NT) or engineered T cells. Tumor cell load in mice was monitored by bioluminescence imaging. Representative data from two independent experiments are shown

Back to article page